{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:49:06Z","timestamp":1792788546283,"version":"4.5.0"},"reference-count":73,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease with inflammatory synovitis. Iguratimod (IGU) combined with methotrexate (MTX) therapy may have better efficacy and safety.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> First, we searched randomized controlled trials (RCTs) of IGU + MTX in the treatment of RA through literature databases (such as PubMed, Corkland Library, CNKI, etc.) and then conducted RCT quality assessment and data extraction. Finally, we used RevMan 5.3 for meta-analysis, STATA 15.0 for publication bias assessment, and GRADE tool for the evidence quality assessment of primary outcomes. This systematic review and meta-analysis were registered in PROSPERO (CRD42021220780).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> This systematic review and meta-analysis included 31 RCTs involving 2,776 patients. Compared with MTX alone, the ACR20, ACR50, and ACR70 of IGU + MTX are higher, while DAS28 is lower [ACR20: (RR 1.55, 95% CI 1.14\u20132.13, <jats:italic>p<\/jats:italic> = 0.006); ACR50: (RR 2.04, 95% CI 1.57\u20132.65, <jats:italic>p<\/jats:italic> &amp;lt; 0.00001); ACR70: (RR 2.19, 95% CI 1.44\u20133.34, <jats:italic>p<\/jats:italic> = 0.00003); DAS28: (weighted mean difference (WMD) \u22121.65, 95% CI \u22122.39 to \u22120.91, <jats:italic>p<\/jats:italic> &amp;lt; 0.0001)]. Compared with MTX + leflunomide, IGU + MTX has no significant difference in improving ACR20, ACR50, ACR70, but IGU + MTX improves DAS28 more significantly [ACR20: (RR 1.09, 95% CI 0.79\u20131.89, <jats:italic>p<\/jats:italic> = 0.59); ACR50: (RR 1.07, 95% CI 0.64\u20131.78, <jats:italic>p<\/jats:italic> = 0.81); ACR70: (RR 1.17, 95% CI 0.44\u20133.10, <jats:italic>p<\/jats:italic> = 0.76); DAS28: (WMD \u22120.40, 95% CI \u22120.42 to \u22120.38, <jats:italic>p<\/jats:italic> &amp;lt; 0.0001)]. Compared with the MTX + tripterygium subgroup and MTX-only subgroup, the incidence of adverse events of the IGU + MTX group is of no statistical significance [MTX only: (RR 0.99, 95% CI 0.87\u20131.13, <jats:italic>p<\/jats:italic> = 0.90); MTX + Tripterygium: (RR 0.73, 95% CI 0.29\u20131.85, <jats:italic>p<\/jats:italic> = 0.50)]. However, compared with MTX + leflunomide, the incidence of adverse events in the IGU + MTX group was lower (RR 0.74, 95% CI 0.62\u20130.88, <jats:italic>p<\/jats:italic> = 0.0009). The quality of ACR70 was high; the quality of adverse events and ACR50 test was moderate.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Compared with conventional therapy, IGU + MTX may be a safer and more effective therapy for RA patients. When the intervention method is (IGU 25\u00a0mg Bid, MTX 10\u201325\u00a0mg once a week), and the intervention lasts for at least 12\u00a0weeks, the curative effect may be achieved without obvious adverse events.<\/jats:p>","DOI":"10.3389\/fphar.2021.780154","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T07:26:11Z","timestamp":1642490771000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["The Effect and Safety of Iguratimod Combined With Methotrexate on Rheumatoid Arthritis: A Systematic Review and Meta-Analysis Based on a Randomized Controlled Trial"],"prefix":"10.3389","volume":"12","author":[{"given":"Liuting","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganpeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wensa","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"key":"B1","article-title":"The Effect of Iguratimod Combined with Methotrexate on Serum VEGF Levels in Patients with Rheumatoid Arthritis and Evaluation of the efficacy","author":"Bi","year":"2019"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/S0140-6736(17)31491-5","article-title":"Novel Treatment Strategies in Rheumatoid Arthritis","volume":"389","author":"Burmester","year":"2017","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3969\/j.issn.1005-4561.2018.07.010","article-title":"Effects of Iguratimod Combined with Methotrexate on Serum Inflammatory Factors and Bone Metabolism in Patients with Rheumatoid Arthritis","volume":"28","author":"Chen","year":"2018","journal-title":"Zhejiang J. Integrated Traditional Chin. West. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s00393-020-00944-7","article-title":"Efficacy and Safety of Iguratimod Combined with Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis : A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"80","author":"Chen","year":"2021","journal-title":"Z. Rheumatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3760\/cma.j.issn.0578-1426.2018.04.004","article-title":"2018 Chinese Guideline for the Diagnosis and Treatment of Rheumatoid Arthritis","volume":"57","year":"2018","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"B6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.7619\/jcmp.201903020","article-title":"Observation on the Effect of Iguratimod Combined with Leflunomide in the Treatment of Moderate and Severe Elderly Active Rheumatoid Arthritis","volume":"23","author":"Dai","year":"2019","journal-title":"J. Clin. Med. Pract."},{"key":"B7","first-page":"2021","article-title":"Chapter 8: Assessing Risk of Bias in Included Studies","volume-title":"Cochrane Handbook or Systematic Reviews of Interventions Version 6.2.0","author":"Deeks","year":""},{"key":"B8","first-page":"2021","article-title":"Chapter 9: Analyzing Data and Undertaking Meta-Analyses","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Deeks","year":""},{"key":"B9","volume-title":"The Effect of Iguratimod on the Proliferation and Migration of Fibroblast-like Synovial Cells in Rheumatoid Arthritis and the Clinical observation","author":"Deng","year":"2017"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.3969\/j.issn.1004-0412.2019.06.041","article-title":"Efficacy and Bone Metabolism Analysis of Iguratimod on Senile Rheumatoid Arthritis","volume":"40","author":"Ding","year":"2019","journal-title":"Jilin Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s10067-015-2999-6","article-title":"Efficacy and Safety Evaluation of a Combination of Iguratimod and Methotrexate Therapy for Active Rheumatoid Arthritis Patients: a Randomized Controlled Trial","volume":"34","author":"Duan","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1080\/14397595.2018.1486939","article-title":"The Add-On Effectiveness and Safety of Iguratimod in Patients with Rheumatoid Arthritis Who Showed an Inadequate Response to Tocilizumab","volume":"29","author":"Ebina","year":"2019","journal-title":"Mod. Rheumatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.15887\/j.cnki.13-1389\/r.2020.33.031","article-title":"The Clinical Efficacy of Iguratimod Combined with Methotrexate in the Treatment of Rheumatoid Arthritis","volume":"13","author":"Fan","year":"2020","journal-title":"J. Clin. Rational Use"},{"key":"B14","first-page":"721","article-title":"One Year in Review 2017: Novelties in the Treatment of Rheumatoid Arthritis","volume":"35","author":"Ferro","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"B15","volume-title":"GRADEpro Guideline Development Tool [Software]","author":"GRADEpro","year":"2015"},{"key":"B16","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3969\/j.issn.1009-4393.2020.25.057","article-title":"The Clinical Efficacy of Ilamud Combined with Methotrexate in the Treatment of Early Rheumatoid Arthritis (RA)","volume":"26","author":"Gu","year":"2020","journal-title":"Contemp. Med."},{"key":"B17","volume-title":"GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. Updated October 2013","author":"Sch\u00fcnemann","year":"2013"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.13748\/j.cnki.issn1007-7693.2014.10.029","article-title":"Observation on the Short-Term Clinical Efficacy of Iguratimod on Rheumatoid Arthritis Complicated with Chronic Interstitial Pneumonia","volume":"31","author":"Hao","year":"2014","journal-title":"China Mod. Appl. Pharm."},{"key":"B19","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3109\/14397595.2013.843756","article-title":"Safety and Efficacy of Combination Therapy of Iguratimod with Methotrexate for Patients with Active Rheumatoid Arthritis with an Inadequate Response to Methotrexate: an Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Trial","volume":"24","author":"Hara","year":"2014","journal-title":"Mod. Rheumatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s00296-017-3726-1","article-title":"Prevalence of Rheumatoid Arthritis in the United States Adult Population in Healthcare Claims Databases, 2004-2014","volume":"37","author":"Hunter","year":"2017","journal-title":"Rheumatol. Int."},{"key":"B21","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s10165-012-0724-8","article-title":"Concomitant Iguratimod Therapy in Patients with Active Rheumatoid Arthritis Despite Stable Doses of Methotrexate: a Randomized, Double-Blind, Placebo-Controlled Trial","volume":"23","author":"Ishiguro","year":"2013","journal-title":"Mod. Rheumatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"109704","DOI":"10.1016\/j.biopha.2019.109704","article-title":"Molecular Mechanisms and Clinical Application of Iguratimod: A Review","volume":"122","author":"Jiang","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3969\/j.issn.2095-4174.2020.09.018","article-title":"The Latest Research Progress in the Clinical Application and Mechanism of Iramud","volume":"9","author":"Jin","year":"2020","journal-title":"Rheum. Arthritis"},{"key":"B24","first-page":"106","article-title":"Evaluation of the Clinical Efficacy of Methotrexate and Ilamod in the Treatment of Refractory Rheumatoid Arthritis","volume":"58","author":"Ju","year":"2020","journal-title":"China Mod. Doctor"},{"key":"B25","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/1756-185X.13513","article-title":"2018 Update of the APLAR Recommendations for Treatment of Rheumatoid Arthritis","volume":"22","author":"Lau","year":"2019","journal-title":"Int. J. Rheum. Dis."},{"key":"B26","first-page":"2981","article-title":"The Effect of Irammod Combined with Methotrexate in the Treatment of Rheumatoid Arthritis with Peripheral Blood Nuclear Factor Kappa B Receptor Activator Ligand and Bone Protective Factor","volume":"20","author":"Li Ch","year":"2020","journal-title":"Chin. Medicines Clin."},{"key":"B27","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3969\/j.issn.1000-7377.2016.01.049","article-title":"The Treatment of 84 Cases of Senile Rheumatoid Arthritis with the Combination of Iguratimod and Methotrexate","volume":"45","author":"Li","year":"2016","journal-title":"Shaanxi Med. J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3969\/j.issn.1006-4931.2019.07.020","article-title":"A Clinical Study on the Treatment of Early Rheumatoid Arthritis by Iguratimod Combined with Methotrexate","volume":"28","author":"Li","year":"2019","journal-title":"China Pharmaceuticals"},{"key":"B29","first-page":"911","article-title":"Cell Therapies for Refractory Rheumatoid Arthritis","volume":"36","author":"Liu","year":"2018","journal-title":"Clin. Exp. Rheumatol."},{"key":"B30","volume-title":"A Comparative Study on the Curative Effect of Methotrexate Combined with Ilamod in the Treatment of Rheumatoid Arthritis with Different Syndromes of Traditional Chinese medicine","author":"Liu","year":"2016"},{"key":"B31","volume-title":"The Therapeutic Effect of Combined Application of Iguratimod and Methotrexate on Active Rheumatoid arthritis","author":"Lu","year":"2014"},{"key":"B32","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1002\/art.24643","article-title":"Multicenter, Randomized, Double-Blind, Controlled Trial of Treatment of Active Rheumatoid Arthritis with T-614 Compared with Methotrexate","volume":"61","author":"Lu","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3969\/j.issn.1000-744X.2018.07.025","article-title":"A Comparative Study on the Efficacy of Methotrexate Combined with Ilamud in the Treatment of Rheumatoid Arthritis with Different Syndromes of Traditional Chinese Medicine","volume":"7","author":"Lu","year":"2018","journal-title":"Rheum. Arthritis"},{"key":"B34","first-page":"137","article-title":"The Effect of Methotrexate Combined with Ilamud in the Treatment of Refractory Rheumatoid Arthritis","volume":"13","author":"Meng","year":"2016","journal-title":"China Med. Herald"},{"key":"B35","doi-asserted-by":"publisher","first-page":"40","DOI":"10.13429\/j.cnki.cjcr.2015.12.010","article-title":"Short-term Clinical Efficacy of Methotrexate Combined with Iguratimod on Refractory Rheumatoid Arthritis","volume":"28","author":"Meng","year":"2015","journal-title":"Chin. J. Clin. Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.13699\/j.cnki.1001-6821.2017.12.008","article-title":"Clinical Study on the Treatment of Senile Rheumatoid Arthritis with Iguratimod Tablets Combined with Methotrexate Tablets","volume":"33","author":"Meng","year":"2017","journal-title":"Chin. J. Clin. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1080\/14397595.2018.1460230","article-title":"Safety and Effectiveness of Iguratimod in Patients with Rheumatoid Arthritis: Final Report of a 52-week, Multicenter Postmarketing Surveillance Study","volume":"29","author":"Mimori","year":"2019","journal-title":"Mod. Rheumatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"156","DOI":"10.16121\/j.cnki.cn45-1347\/r.2015.02.06","article-title":"Clinical Study on the Treatment of Active Rheumatoid Arthritis with Iguratimod Combined with Methotrexate","volume":"10","author":"Mo","year":"2015","journal-title":"Intern. Med."},{"key":"B39","first-page":"40","article-title":"A Randomized Controlled Trial of Methotrexate Combined with Iguratimod in the Treatment of Active Rheumatoid Arthritis","volume":"52","author":"Mo","year":"2018","journal-title":"J. Fujian Med. Univ."},{"key":"B40","doi-asserted-by":"publisher","first-page":"100128","DOI":"10.1016\/j.lanwpc.2021.100128","article-title":"Effectiveness and Safety of Iguratimod Treatment in Patients with Active Rheumatoid Arthritis in Chinese: A Nationwide, Prospective Real-World Study","volume":"10","author":"Mu","year":"2021","journal-title":"Lancet Reg. Health West. Pac."},{"key":"B41","doi-asserted-by":"publisher","first-page":"534","DOI":"10.3109\/14397595.2014.998361","article-title":"Efficacy at 52 Weeks of Daily Clinical Use of Iguratimod in Patients with Rheumatoid Arthritis","volume":"25","author":"Okamura","year":"","journal-title":"Mod. Rheumatol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"534","DOI":"10.3109\/14397595.2014.998361","article-title":"Efficacy at 52 Weeks of Daily Clinical Use of Iguratimod in Patients with Rheumatoid Arthritis","volume":"25","author":"Okamura","year":"","journal-title":"Mod. Rheumatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"101477","DOI":"10.1016\/j.berh.2019.101477","article-title":"The Epidemiology of Established Rheumatoid Arthritis","volume":"33","author":"Ot\u00f3n","year":"2019","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3969\/j.issn.2095-3593.2019.03.015","article-title":"Study on the Efficacy and Safety of Methotrexate and Isilamod in the Treatment of Rheumatoid Arthritis","volume":"36","author":"Qi","year":"2019","journal-title":"Chin. J. Drug Eval."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid Arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"key":"B46","doi-asserted-by":"publisher","first-page":"33","DOI":"10.13764\/j.cnki.ncdm.2015.01.010","article-title":"Efficacy and Safety of Methotrexate Combined with Iguratimod in the Treatment of Active Rheumatoid Arthritis","volume":"55","author":"Shi","year":"2015","journal-title":"J. Nanchang Univ. (Medical Edition)"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1007\/s10067-020-04986-9","article-title":"Relative Efficacy and Safety of Iguratimod Monotherapy for the Treatment of Patients with Rheumatoid Arthritis: a Systematic Review and Meta-Analysis","volume":"39","author":"Shrestha","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"B49","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: 2016 Update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/14397595.2018.1510879","article-title":"The Three-Year Efficacy of Iguratimod in Clinical Daily Practice in Patients with Rheumatoid Arthritis","volume":"29","author":"Suto","year":"2019","journal-title":"Mod. Rheumatol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3969\/j.issn.1003-6350.2017.03.015","article-title":"The Effect of Iguratimod Combined with Methotrexate on Serum M-CSF, IL-6, IL-8 and Bone Metabolism in Patients with Rheumatoid Arthritis","volume":"28","author":"Tian","year":"2017","journal-title":"Hainan Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3760\/cma.j.issn.1007-7480.2020.03.002","article-title":"Efficacy and Safety of Ellamod or Leflunomide Combined with Methotrexate in the Treatment of Active Rheumatoid Arthritis Sexual Comparison: a Multicenter Randomized Double-Blind Double-Simulation Controlled Clinical Study","volume":"24","author":"Tian","year":"2020","journal-title":"Chin. J. Rheumatol."},{"key":"B54","first-page":"231","article-title":"Clinical Study on the Treatment of Rheumatoid Arthritis with Methotrexate Tablets Combined with Iguratimod Tablets","volume":"35","author":"Wang","year":"2019","journal-title":"Chin. J. Clin. Pharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s10067-017-3668-8","article-title":"Effects of Iguratimod on the Levels of Circulating Regulators of Bone Remodeling and Bone Remodeling Markers in Patients with Rheumatoid Arthritis","volume":"36","author":"Wang","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"B56","volume-title":"Study on the Effect of Iguratimod on Bone Metabolism in Patients with Rheumatoid arthritis","author":"Wang","year":"2017"},{"key":"B57","first-page":"1245","article-title":"Diagnosis and Management of Rheumatoid Arthritis","volume":"84","author":"Wasserman","year":"2011","journal-title":"Am. Fam. Physician"},{"key":"B58","first-page":"455","article-title":"Rheumatoid Arthritis: Common Questions about Diagnosis and Management","volume":"97","author":"Wasserman","year":"2018","journal-title":"Am. Fam. Physician"},{"key":"B59","doi-asserted-by":"publisher","first-page":"76","DOI":"10.13638\/j.issn.1671-4040.2020.11.037","article-title":"Observation on the Effects of Iguratimod and Tripterygium Glycosides in the Treatment of Rheumatoid Arthritis","volume":"20","author":"Xia","year":"2020","journal-title":"Pract. Integrated Traditional Chin. West. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1007\/s00393-015-1641-y","article-title":"Iguratimod in Combination with Methotrexate in Active Rheumatoid Arthritis : Therapeutic Effects","volume":"75","author":"Xia","year":"2016","journal-title":"Z. Rheumatol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"831","DOI":"10.3969\/j.issn.1000-744X.2018.07.025","article-title":"The Effect of Iguratimod Combined with MTX on IL-1, Serum TNF-\u03b1 and VEGF Levels in Patients with Refractory Rheumatoid Arthritis","volume":"42","author":"Xie","year":"2018","journal-title":"Guizhou Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fphar.2020.00073","article-title":"Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape","volume":"11","author":"Xie","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3969\/j.issn.1004-437X.2020.01.044","article-title":"The Clinical Efficacy of Methotrexate Combined with Iguratimod on Active Rheumatoid Arthritis","volume":"29","author":"Xiong","year":"2020","journal-title":"Henan Med. Res."},{"key":"B64","doi-asserted-by":"publisher","first-page":"120","DOI":"10.7619\/jcmp.201501038","article-title":"Clinical Study of Methotrexate Combined with Ilamud in the Treatment of Rheumatoid Arthritis","volume":"19","author":"Xu","year":"","journal-title":"J. Clin. Med. Pract."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.3969\/j.issn.1009-0959.2017.10.015","article-title":"The Curative Effect of Methotrexate, Isilamod Combined with Physical Therapy on Patients with Rheumatoid Arthritis and the Effects of RF, ESR and CRP","volume":"19","author":"Xu","year":"","journal-title":"China Med. Guide"},{"key":"B66","doi-asserted-by":"publisher","first-page":"47","DOI":"10.15912\/j.cnki.gocm.2017.22.031","article-title":"Clinical Observation on the Treatment of Rheumatoid Arthritis with Iguratimod Combined with Methotrexate","volume":"15","author":"Xu","year":"","journal-title":"Guide Chin. Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3969\/j.issn.1001-9057.2015.12.014","article-title":"Study on the Effect of Iguratimod Combined with Methotrexate Treatment on Anti-cyclic Guanidine Peptide Antibodies and Other Indicators in Patients with Rheumatoid Arthritis","volume":"32","author":"Xu","year":"","journal-title":"J. Clin. Intern. Med."},{"key":"B68","doi-asserted-by":"publisher","first-page":"369","DOI":"10.13463\/j.cnki.cczyy.2018.02.054","article-title":"Effect of Iguratimod Combined with Methotrexate on Serum-Related Cytokines and Bone Metabolism in Patients with Rheumatoid Arthritis","volume":"34","author":"Yan","year":"2018","journal-title":"J. Changchun Univ. Traditional Chin. Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/14397595.2017.1336865","article-title":"Add-on Iguratimod as a Therapeutic Strategy to Achieve Remission in Patients with Rheumatoid Arthritis Inadequately Responding to Biological DMARDs: A Retrospective Study","volume":"28","author":"Yoshikawa","year":"2018","journal-title":"Mod. Rheumatol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3109\/14397595.2015.1069475","article-title":"Disease Activity Early in Treatment as a Predictor of Future Low Disease Activity in RA Patients Treated with Iguratimod","volume":"26","author":"Yoshioka","year":"2016","journal-title":"Mod. Rheumatol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"98","DOI":"10.15912\/j.cnki.gocm.2014.01.111","article-title":"Clinical Observation of MTX Combined with Iguratimod in the Treatment of Refractory Rheumatoid Arthritis","volume":"1","author":"Zhang","year":"2014","journal-title":"Chin. Med. Guide"},{"key":"B72","doi-asserted-by":"publisher","first-page":"44","DOI":"10.19347\/j.cnki.2096-1413.201815020","article-title":"The Clinical Effect of Iguratimod Combined with Methotrexate in the Treatment of Rheumatoid Arthritis","volume":"3","author":"Zhao","year":"2018","journal-title":"Clin. Med. Res. Pract."},{"key":"B73","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3760\/cma.j.jssn.1673-4904.2016.05.017","article-title":"Clinical Study of Iguratimod in the Treatment of Active Rheumatoid Arthritis","volume":"39","author":"Zhao","year":"2016","journal-title":"Chin. J. Postgraduates Med."},{"key":"B74","volume-title":"Clinical Observation of Iguratimod in the Treatment of Rheumatoid arthritis","author":"Zhu","year":"2019"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.780154\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T07:26:55Z","timestamp":1642490815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.780154\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":73,"alternative-id":["10.3389\/fphar.2021.780154"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.780154","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,18]]},"article-number":"780154"}}